# PureTech Health (PRTC) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/PRTC
## Company Profile
- Ticker: PRTC
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United Kingdom
## Stock Data
- Close: 17.42 USD
- Market cap: 424034486.98 USD
- Last updated: 2026-05-20
## Business Overview
### Founded-Entity Model
PureTech Health creates and advances biotechnology companies around internally identified scientific concepts. Rather than operating as a conventional single-pipeline developer, it retains ownership interests and economic rights across a portfolio of independently financed founded entities.
### Celea Therapeutics
Celea is developing deupirfenidone, formerly LYT-100, for idiopathic pulmonary fibrosis. The deuterated pirfenidone candidate completed the Phase 2b ELEVATE IPF study and is Phase 3 ready for the head-to-head SURPASS-IPF trial against pirfenidone.
### Gallop Oncology
Gallop is advancing LYT-200, an anti-galectin-9 antibody, for relapsed or refractory myeloid malignancies. Phase 1b data in high-risk myelodysplastic syndrome and acute myeloid leukemia provide clinical validation for a planned next stage of development.
### Seaport Therapeutics
Seaport applies the Glyph platform to neuropsychiatric medicines designed for lymphatic transport and enhanced exposure. Its pipeline includes GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder and associated sleep disturbance.
### Portfolio Value Creation
PureTech seeks to create value by separating programs into focused companies, attracting external capital and partners, and retaining equity or contractual economics. This structure allows different assets to progress with dedicated management and financing.
## Why The Stock Is Moving

Current closing-price context is not available for PRTC.

## Future Catalysts

- Initiation of Celea’s Phase 3 SURPASS-IPF trial near the closing of its planned financing.
- Topline Phase 2b BUOY-1 data for GlyphAllo expected in the first half of 2027.
- Phase 2a GlyphAgo sleep-study results expected in early 2028 and Phase 2b GAD results expected by year-end 2028.

## Recent News
- 2026-07-13 06:00 EST — [PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)](https://biopharmsignal.com/news/PRTC/puretech-founded-entity-celea-therapeutics-doses-first-patient-in-global-phase-3-ca178bb0) — Source: PureTech Health
- 2026-07-02 06:01 EST — [PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)](https://biopharmsignal.com/news/PRTC/puretech-founded-entity-celea-therapeutics-completes-180-million-financing-to-ad-3954c132) — Source: PureTech Health
- 2026-07-02 06:00 EST — [PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)](https://biopharmsignal.com/news/PRTC/puretech-announces-completion-of-180-million-financing-for-founded-entity-celea--b2099580) — Source: PureTech Health
- 2026-06-10 16:38 EST — [Results of Annual General Meeting](https://biopharmsignal.com/news/PRTC/results-of-annual-general-meeting-3242a586) — Source: PureTech Health
- 2026-06-09 06:00 EST — [PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers](https://biopharmsignal.com/news/PRTC/puretech-founded-entity-seaport-therapeutics-reports-positive-multiple-ascending-7098585c) — Source: PureTech Health